Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study
Autor: | Samer Qara, Mustafa Saad, Jehad Alhashem, Ali Mansour, Mahmoud Mustafa, Gasmelseed Y. Ahmed, Zainab Almoosa, Mohammed ALzain, Duaa Alshab, Neda’a Anshasi, Sajida ALKhawajah, Mokhtar ALmarzooq, Saleh Alkhalifah, Abbas Al Mutair |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Standard of care Coronavirus disease 2019 (COVID-19) Infectious and parasitic diseases RC109-216 Favipiravir Antiviral Agents Internal medicine Medicine Antiviral therapy and standard therapy Humans In patient Retrospective Studies business.industry SARS-CoV-2 Public Health Environmental and Occupational Health COVID-19 Retrospective cohort study Standard of Care General Medicine Pneumonia medicine.disease Amides Clinical trial Infectious Diseases Treatment Outcome Pyrazines Original Article Public aspects of medicine RA1-1270 business Standard therapy |
Zdroj: | Journal of Infection and Public Health Journal of Infection and Public Health, Vol 14, Iss 9, Pp 1247-1253 (2021) |
ISSN: | 1876-035X 1876-0341 |
Popis: | Objective To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection. Methods This is a retrospective cohort of patients with COVID-19 pneumonia who were treated with favipiravir, versus comparison group that received the standard of care. Results A total of 226 patients were included; 110 patients received favipiravir and 116 patients received standard of care. Patients who received favipiravir had longer time to recovery (14.2 ± 8.8 versus 12.8 ± 5.2, p = 0.17). Favipiravir was associated with an improved early day 14 mortality (4 [3.6%] versus 11 [9.5%]), p = 0.008), but was associated with a higher day 28 mortality (26 [23.6%] versus 11 [9.5%], p = 0.02). The overall mortality was higher in the favipiravir versus the standard of care group but difference was not statistically significant (33 [30.0%] versus 24 [20.7%], p = 0.10). Conclusion The addition of favipiravir to standard of care was not associated with any improvement in clinical outcomes or mortality. Larger randomized controlled clinical trials are needed to further assess the efficacy of favipiravir. |
Databáze: | OpenAIRE |
Externí odkaz: |